Kaluzny A, Brawley O, Garson-Angert D, Shaw J, Godley P, Warnecke R, Ford L
Cecil G. Sheps Center for Health Services Research, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599-7590.
J Natl Cancer Inst. 1993 Dec 1;85(23):1945-50. doi: 10.1093/jnci/85.23.1945.
The Minority-Based Community Clinical Oncology Program (MBCCOP) was initiated in September 1990 to expand the National Cancer Institute's (NCI's) clinical trials network to minority populations. Institutions, organizations, and/or physician groups that had more than 50% of new cancer patients from minority groups were eligible to participate. There has been no previous evaluation of the MBCCOP.
This study was designed to describe the early implementation of the MBCCOP and identify the challenges that have emerged in developing a network aimed at increasing the participation of minority populations in clinical trials.
Data were taken from primary and secondary sources, including site visits and patient log data, that described performance of 12 MBCCOP centers initially funded in September 1990. Accrual was measured by the number of credits earned per MBCCOP for patients enrolled in research protocols for cancer treatment or for prevention and control, which includes activities such as early detection, pain control, and rehabilitation. These accrual credits, assigned by the NCI, were based on the complexity of the protocol and the amount of resources expected to be required for accrual of patients by the MBCCOP.
Data for the first 2 years of the MBCCOP showed that 344 patients were accrued to trials of treatment protocols from June 1, 1990, to May 31, 1991, and this number increased to 470 during the second accrual year, June 1, 1991, to May 31, 1992. Similarly, accrual of patients to cancer prevention and control studies increased from 256 in 1990-1991 to 423 in 1991-1992. More than 70% of the MBCCOP patients entered in studies were from minority populations. The proportion of eligible MBCCOP patients entered into treatment protocols was identical with that experienced by the initial Community Clinical Oncology Program (CCOP). Results also demonstrated that MBCCOP centers operate in an environment characterized by socio-economic decline and limited resources, both having substantial effects on the implementation of clinical trials among minorities. While minority patients are willing to participate in clinical trials, there are profound barriers involving language, logistics, and the appropriateness of available protocols. Participating physicians, nurses, and support personnel report a high level of agreement with program goals and have developed unique approaches to meeting the challenges faced in the implementation of this program.
The MBCCOPs have demonstrated their ability to participate in clinical trials. Evaluation reveals, however, that they are emerging organizations influenced by factors endemic to the community they serve and their own structure. The MBCCOPs are confronting substantial challenges, yet they provide an important link to the overall NCI clinical trials network.
基于少数族裔的社区临床肿瘤项目(MBCCOP)于1990年9月启动,旨在将美国国立癌症研究所(NCI)的临床试验网络扩展至少数族裔人群。新癌症患者中超过50%来自少数族裔群体的机构、组织和/或医师团体有资格参与。此前尚未对MBCCOP进行过评估。
本研究旨在描述MBCCOP的早期实施情况,并确定在建立一个旨在增加少数族裔人群参与临床试验的网络过程中出现的挑战。
数据取自主要和次要来源,包括实地考察和患者日志数据,这些数据描述了1990年9月最初获得资助的12个MBCCOP中心的表现。入组情况通过每个MBCCOP为参与癌症治疗或预防与控制研究方案的患者赚取的学分数量来衡量,其中包括早期检测、疼痛控制和康复等活动。这些由NCI分配的入组学分基于方案的复杂性以及MBCCOP预计为招募患者所需的资源量。
MBCCOP头两年的数据显示,从1990年6月1日至1991年5月31日,有344名患者入组治疗方案试验,在第二个入组年,即1991年6月1日至1992年5月31日,这一数字增至470名。同样,参与癌症预防与控制研究的患者人数从1990 - 1991年的256名增至1991 - 1992年的423名。参与研究的MBCCOP患者中超过70%来自少数族裔人群。符合条件的MBCCOP患者进入治疗方案的比例与最初的社区临床肿瘤项目(CCOP)相同。结果还表明,MBCCOP中心在社会经济衰退和资源有限的环境中运作,这两者对少数族裔人群临床试验的实施都有重大影响。虽然少数族裔患者愿意参与临床试验,但存在涉及语言、后勤以及现有方案适用性等方面的重大障碍。参与项目的医生、护士和支持人员对项目目标高度认同,并已开发出独特方法来应对该项目实施过程中面临的挑战。
MBCCOP已证明其参与临床试验的能力。然而,评估显示,它们是受其所服务社区的特有因素及其自身结构影响的新兴组织。MBCCOP面临着重大挑战,但它们为整个NCI临床试验网络提供了重要联系。